LYTENAVA
Dead / Abandoned — Abandoned — failure to respond (as of 22 May 2024)
What this means for you
This application is over — abandoned 09 May 2024. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 88872045
- Mark type
- Stylized text
- Filed
- 14 Apr 2020
- Published for opposition
- 04 Aug 2020
- Abandoned
- 09 May 2024
- Attorney of record
- Ariana G. Hiscott
Goods and services
- Class 005 — Pharmaceuticals: injectable pharmaceutical preparations for the treatment of retinal disease; pharmaceuticals, namely, ophthalmic drugs for the treatment of retinal disease
Owner
- Outlook Therapeutics, Inc., Iselin, NJ, US
- Outlook Therapeutics, Inc., Cranbury, NJ, US
Prosecution history
- 22 May 2024 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 22 May 2024 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 05 Feb 2024 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 05 Feb 2024 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 08 Nov 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 08 Nov 2023 — NON-FINAL ACTION E-MAILED
- 08 Nov 2023 — SU - NON-FINAL ACTION - WRITTEN
- 18 Sept 2023 — STATEMENT OF USE PROCESSING COMPLETE
- 14 Sept 2023 — USE AMENDMENT FILED
- 14 Sept 2023 — TEAS STATEMENT OF USE RECEIVED
- 23 Mar 2023 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Mar 2023 — SOU EXTENSION 5 GRANTED
- 13 Mar 2023 — SOU EXTENSION 5 FILED
- 22 Mar 2023 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 13 Mar 2023 — SOU TEAS EXTENSION RECEIVED